81 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
Employee or a Consultant Company, the Optionee's employer, ceases to be an Eligible Person as a result of termination for cause as that term … is interpreted by the courts of the jurisdiction in which the Optionee, or, in the case of a Management Company Employee or a Consultant Company
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
9 Aug 23
Statement of Executive Compensation
7:41pm
or Disability; and
(ii)
the Expiry Date;
(b) Termination For Cause
If the Optionee or, in the case of a Management Company Employee or a Consultant … of the jurisdiction in which the Optionee, or, in the case of a Management Company Employee or a Consultant Company, of the Optionee’s employer, is employed
20-F/A
2021 FY
REPCF
Replicel Life Sciences Inc.
12 Sep 22
Annual report (foreign) (amended)
6:17pm
was settled by the issuance of common shares. This individual is an employee at MainPointe Pharmaceuticals LLC.
During the year ended December 31 … company on a regular basis and report to the Board.
D. Employees
As of December 31, 2021, we had one full time employee and one contractor
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
7 Jul 22
Statement of Executive Compensation
1:43pm
of the options vesting in any three month period.
If a director, employee or consultant of the Company is terminated for cause or resigns, then any option … granted to the option holder will terminate immediately upon the option holder ceasing to be a director, employee, or consultant by reason
6-K
EX-99.1
z0lyfgjo8tco
30 Jun 22
Statement of Executive Compensation
11:16am
6-K
EX-99.1
kkmxa0
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
p802m3p
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.1
3vc9d0fsoa1hm23nfap
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
mggzolpv8aya 1u
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm
20-F/A
y9q7 ip93ldq
31 Mar 21
Annual report (foreign) (amended)
12:00am
6-K
EX-99.4
8cp k6k52473ow
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.2
la0rabh
22 Dec 20
Current report (foreign)
3:05pm
6-K
EX-99.1
1x36koengsss1g7c3xnw
13 Nov 20
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.1
dc0 z95tydcr1d
3 Aug 20
Consolidated Financial Statements
12:00am
6-K
EX-99.1
zrtdnej9z3a9m053w
6 Nov 19
Notice of Annual General and Special Meeting of Shareholders
12:00am